Company attributes
Other attributes
Shield Bio, formerly known as TL Biolabs, was a biotechnology company offering a DNA sequencing platform for helping to prevent antibiotic resistance headquartered in San Jose, California. It was founded in 2016 by Fred Turner and Sam Parlett.
The company's platform allowed for the genomic testing and identification of antibiotic strains of gonorrhea, and other pathogens exhibiting antibiotic resistance.
On February 23, 2017 Shield Bio announced raising $4.1 million in seed funding from Andreessen Horowitz (lead investor), Soma Capital, SGH Capital, Refactor Capital, Friale, and Josh Buckley.
On May 23, 2018 Shield Bio announced raising $8 million in series A funding from Refactor Capital (lead investor), Andreessen Horowitz (lead investor), iSELECT FUND, Zeno Ventures, Y Combinator, Valia Ventures, Tectonic Capital, Summit Action, Sinai Ventures, Soma Capital, and Sean Rad.
